Aktieanalys

Medivir: Strategic Pipeline Prioritisation at IGM Biosciences - Redeye

{newsItem.title}

Redeye Publicerad: 06 Dec 2023 14:14

Redeye comments on the cost reduction program at IGM Biosciences which impacts birinapant, which is licensed from Medivir.

Länk till analysen i sin helhet: https://www.redeye.se/research/966077/medivir-strategic-pipeline-prioritisation-at-igm-biosciences?utm_source=finwire&utm_medium=RSS

Nyheter om Medivir

Läses av andra just nu

Om aktien Medivir

Senaste nytt